MASLD is the current name for what was long called non-alcoholic fatty liver disease. It describes the accumulation of fat inside liver cells in people who have metabolic risk factors, such as obesity or insulin resistance, and who drink little or no alcohol. In its early stages the condition is often silent, but over years and decades it can progress to inflammation, scarring known as fibrosis, and eventually cirrhosis or liver cancer. Because the disease develops slowly, researchers have increasingly worried that children who develop hepatic steatosis, the fat accumulation that marks the first stage, may face a lifetime of elevated liver risk.

Estimating how many children actually have MASLD has proven surprisingly difficult. The gold standard for diagnosis is a liver biopsy, an invasive procedure that cannot ethically be performed on healthy children in large numbers. Ultrasound and blood tests are alternatives, but both have limitations: ultrasound is relatively insensitive to mild fat accumulation, and elevated liver enzymes appear only after a degree of liver injury has already occurred. The new study turned instead to vibration-controlled transient elastography, or VCTE, a non-invasive technology that has become a workhorse of adult hepatology and is now being applied at scale to pediatric populations.

VCTE works by sending a small mechanical vibration through the skin into the liver and measuring how fast shear waves travel through the tissue. Fatty liver is stiffer and conducts these waves differently than healthy liver, allowing the device to estimate the amount of fat, expressed as a controlled attenuation parameter, and the degree of fibrosis, expressed as liver stiffness, in a single painless examination that takes only minutes. Because the vibration is actively controlled, the technique is less dependent on the operator’s skill than conventional ultrasound, which makes it well suited to standardized, multi-center studies in which measurements must be comparable across countries and continents.

The scale of the new analysis is what sets it apart. The researchers enrolled 9,352 children and adolescents between the ages of 6 and 18, recruited both from community settings and from hospitals. The median age of participants was 12.0 years, and 58.5 percent were male. Each participant underwent VCTE assessment, allowing the team to classify both the presence of hepatic steatosis and, among those affected, the severity of fat accumulation and any accompanying fibrosis. This dual assessment is rare in pediatric epidemiology, where most prior studies could report only prevalence without grading disease severity.

The headline numbers are striking. In the community population, meaning children recruited outside hospital settings, the prevalence of MASLD was 17.60 percent, with an age-standardized prevalence of 20.97 percent. In the hospital population, where children were presumably referred for metabolic or other health concerns, prevalence reached 58.03 percent, or 52.34 percent after age standardization. The gap between these two figures underscores a critical point for clinicians and public health planners: hospital-based studies, which have historically dominated the literature, substantially overestimate the burden of pediatric MASLD in the general population, even as they reveal how concentrated the disease is among children already carrying metabolic risk.

Geography mattered enormously. Among community-recruited children, South America showed the highest prevalence at 47.92 percent, followed by North America at 25.05 percent and Asia at 13.96 percent. These regional disparities likely reflect differences in the prevalence of childhood obesity, dietary patterns, genetic background, and socioeconomic conditions, although the study’s cross-sectional design means it documents these differences rather than explaining them. Even so, the finding that nearly half of community children in some South American settings show hepatic steatosis on elastography represents a signal that public health systems in those regions may need to prepare for a future wave of chronic liver disease.

The study also captured something that few single-center efforts could: change over time. Comparing adolescents assessed in 2017 through 2020 with those assessed in 2021 through 2024, the researchers found that MASLD prevalence among adolescents was significantly higher in the more recent period. The one exception was telling: among adolescents of normal weight or below, prevalence did not rise. This pattern points strongly to the ongoing rise in pediatric obesity as the engine of increasing fatty liver disease in young people, and it suggests that the pandemic-era years, which saw disruptions to physical activity, diet, and healthcare access for many families, may have accelerated an already worrying trend.

Beyond counting cases, the investigators dug into what drives disease severity, and their analysis yielded a coherent biological picture. Older age, obesity, and elevated serum aminotransferase levels, the liver enzymes that rise when hepatocytes are injured, were independently associated with both hepatic steatosis and fibrosis. More provocatively, the team found that the grade of steatosis itself mattered: children with moderate to severe fat accumulation, classified as grades S2 and S3, were independently more likely to show greater hepatic fibrosis than those with milder steatosis. This suggests that in children, as in adults, the amount of fat in the liver is not merely a benign marker but is linked to the scarring process that ultimately determines prognosis.

For clinicians, the practical implications are considerable. Elevated aminotransferases emerged as an independent flag for both steatosis and fibrosis, reinforcing the value of simple blood tests as a first-line screening tool in overweight children, with VCTE available as a non-invasive second step to grade disease without resorting to biopsy. For researchers, the study provides contemporary, standardized baseline data against which future trends can be measured, something the field has lacked. And for policymakers, the message is harder to ignore: a condition affecting roughly one in five community children, and rising among adolescents, is not a niche hepatology problem but a pediatric metabolic disease that will follow today’s children into adulthood. Whether interventions targeting childhood obesity can bend this curve remains the central question the next decade of research must answer.

Subject of Research: Prevalence and severity of metabolic dysfunction-associated steatotic liver disease in children and adolescents assessed by vibration-controlled transient elastography

Article Title: An international multicenter study of MASLD prevalence among children and adolescents assessed by VCTE

Article References: An international multicenter study of MASLD prevalence among children and adolescents assessed by VCTE. (n.d.). https://doi.org/10.1038/s41467-026-78071-1

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78071-1

Keywords: MASLD, fatty liver disease, pediatrics, VCTE, elastography, hepatic steatosis, fibrosis, obesity, liver disease, epidemiology, children, adolescents